Treatment of short bowel syndrome patients with colon-in-continuity
View Patent ↗Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1. A method for enhancing intestinal absorption in a patient with short bowel syndrome with colon-in-continuity with remnant small intestine, wherein the patient retains colon sufficient to produce at least about 10% of endogenous GLP-2 levels produced by a healthy individual in a fed state, comprising the step of administering to said patient a GLP-2 receptor agonist using a dosing regimen effective to enhance intestinal absorption, wherein said GLP-2 receptor agonist is selected from the group consisting of a GLP-2 peptide, a GLP-2 analog, a derivatized GLP-2 peptide or a derivatized GLP-2 analog.
2. The method according to claim 1 , wherein said enhancement of intestinal absorption is an increase in at least one of a wet weight absorption compared to a baseline wet weight absorption and/or an energy absorption compared to a baseline energy absorption.
3. The method according to claim 2 , wherein said patient has at least 25% colon-in-continuity with remnant small intestine.
4. The method according to claim 3 , wherein said patient has at least 50% colon-in-continuity with remnant small intestine.
5. The method according to claim 4 , wherein said patient has at least 75% colon-in-continuity with remnant small intestine.
6. The method according to claim 2 , wherein said patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 5pmol/L in the fed state.
7. The method according to claim 6 , wherein said patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 10pmol/L in the fed state.
8. The method according to claim 2 , wherein said remnant small intestine has a length of at least 25 cm.
9. The method according to claim 8 , wherein said remnant small intestine has a length of at least 50 cm.
10. The method according to claim 2 , wherein said dosing regimen comprises daily administration of said GLP-2 receptor agonist.
11. The method according to claim 2 , wherein said dosing regimen comprises administration of said GLP-2 receptor agonist over a period of at least 21 days.
12. The method according to claim 2 , wherein said GLP-2 receptor agonist is a mammalian GLP-2.
13. The method according to claim 12 , wherein said GLP-2 receptor agonist is human GLP-2.
14. The method according to claim 2 , wherein said GLP-2 receptor agonist is a GLP-2 analog.
15. The method according to claim 14 , wherein said GLP-2 receptor agonist is a human GLP-2 analog.
16. The method according to claim 15 , wherein said GLP-2 receptor agonist is [Gly2]hGLP-2.
17. The method according to claim 10 , wherein said GLP-2 receptor agonist is administered at a daily dose of from 5 to 500 μg/kg/day.
18. The method according to claim 1 , wherein the patient's short bowel syndrome is secondary to at least one of: Crohn's disease, vascular ischemic disease, mesenteric infarction, malrotation, volvulous, trauma, injury, a congenital anomaly, or a stricture.
19. The method according to claim 18 , wherein the patient's short bowel syndrome is secondary to Crohn's disease.
20. The method according to claim 18 , wherein the patient's short bowel syndrome is secondary to a stricture.
21. The method according to claim 18 , wherein the patient's short bowel syndrome is secondary to mesenteric infarction.
22. The method according to claim 18 , wherein the patient's short bowel syndrome is secondary to volvulous.
23. The method according to claim 20 , wherein the patient's short bowel syndrome is secondary to injury.
24. The method according to claim 1 , wherein the patient produces at least about 20%, 30%, 40%, or 50% of the endogenous GLP-2 plasma levels produced by a healthy individual in the fed state.
25. The method according to claim 1 , wherein the patient produces about 100% of the endogenous GLP-2 plasma levels produced by a healthy individual in the fed state.
26. A method according to claim 1 , wherein the patient produces at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70 pmol/L endogenous GLP-2 plasma levels in the fed state.